Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 10/20 | 0.70 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17310234 | 0.93 | ALK (0.60) | ALKMAPTPDK2 | |
| SCHEMBL17310168 | 0.90 | ALK (0.72) | ALKMAPTSUV39H2 | |
| SCHEMBL17310124 | 0.90 | ALK (0.64) | ALKSUV39H2 | |
| SCHEMBL17310051 | 0.88 | ALK (0.55) | ALKMAPTALDH1A1PDK2 | |
| SCHEMBL15933043 | 0.83 | ALK (1.00) | ALK | |
| Hydrochloric Acid SCHEMBL17310211 | 0.82 | ALK (0.98) | ALK | |
| SCHEMBL17310018 | 0.80 | ALK (0.78) | ALKTRPC6 | |
| SCHEMBL17310196 | 0.78 | TNK2 (0.46) | ALKMAPT | |
| SCHEMBL17404654 | 0.78 | ALK (0.69) | ALK | |
| SCHEMBL15933047 | 0.75 | ALK (0.59) | ALKMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2952510-B1 | SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2018-12-26 | — | — | EP | disclosed |
| US-9708295-B2 | Substituted 2-aminopyridine protein kinase inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-07-18 | — | — | US | disclosed |
| US-20160002205-A1 | SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD (CN) | 2016-01-07 | — | — | US | disclosed |
| EP-2952510-A1 | SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd (CN) | 2015-12-09 | — | — | EP | disclosed |
| CN-104968654-A | Substituted 2-aminopyridine protein kinase inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD | 2015-10-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002205-A1 | SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | PACSIN2, MAPKAPK2, PRKCA | ALK 853/4885TRPC6 2230/4885MAPT 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.